SEC Form 4 · accession 0001161697-26-000172
CATALYST PHARMACEUTICALS, INC. · CPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel J. Curran
Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001369568
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF4 | $21.12 | Jul 15, 2026 | D | 40,000 | D | — | Aug 1, 2032 | Common Stock | 40,000 | 0 | D |
| Options to purchase common stockF4 | $22.77 | Jul 15, 2026 | D | 18,115 | D | — | Nov 20, 2032 | Common Stock | 18,115 | 0 | D |
| Restricted Stock UnitsF1,F4 | — | Jul 15, 2026 | D | 5,468 | D | — | Nov 20, 2028 | Common Stock | 5,468 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F3In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F4Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.